Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Daily

Download Data

Tenaya Therapeutics Inc Price to Sales Ratio (P/S) on June 03, 2024: 17.69

Tenaya Therapeutics Inc Price to Sales Ratio (P/S) is 17.69 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Tenaya Therapeutics Inc 52-week high Price to Sales Ratio (P/S) is 20.71 on May 17, 2024, which is 17.09% above the current Price to Sales Ratio (P/S).
Tenaya Therapeutics Inc 52-week low Price to Sales Ratio (P/S) is 15.75 on May 10, 2024, which is -10.96% below the current Price to Sales Ratio (P/S).
Tenaya Therapeutics Inc average Price to Sales Ratio (P/S) for the last 52 weeks is 18.82.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends